Vimarsana
Biggest News Aggregation in the World

Page 30 - Resented News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Resented. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Resented Today - Breaking & Trending Today

Microbot Medical's LIBERTY® Robotic System Surpasses 100th Catheterization - Vimarsana News

Microbot Medical's LIBERTY® Robotic System Surpasses 100th Catheterization

95% success rate of reaching pre-determined vascular target with no intraoperative complications presented during pre-clinical studiesHINGHAM, Mass., May 03, 2023 -- Microbot Medical Inc. , the... | May 3, 2023

Teamviewer slumps - business with major customers disappoints - Vimarsana News

Teamviewer slumps - business with major customers disappoints

A slowdown in business with major customers put pressure on Teamviewer shares on Wednesday. The paper of the software specialist, which had presented its quarterly report this morning, lost 11.4... | May 3, 2023

Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue Regeneration - Vimarsana News

Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue Regeneration

– Data presented at 2023 Annual Meeting of the Wound Healing Society showed statistically significant results characterizing the in vivo bioactivity of Ceapro’s oat-derived bioactive... | May 3, 2023

Bulletin from TF Bank AB's Annual General Meeting 2023 - Vimarsana News

Bulletin from TF Bank AB's Annual General Meeting 2023

The material resolutions passed at TF bank's Annual General Meeting earlier today on 3 May 2023 are presented below. The meeting was held in Wigge & Partners Advokat KB's offices in Stockholm and... | May 3, 2023

Moderna, Inc.: Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia to be Presented at the 2023 ASGCT Annual Meeting - Vimarsana News

Moderna, Inc.: Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia to be Presented at the 2023 ASGCT Annual Meeting

After completing enrollment in 5 dose cohorts, and with no dose-limiting safety signals observed to date by the independent DSMB, the Phase 1/2 trial of mRNA-3927 advances to the dose-expansion phase to